Shandong New Time Pharmaceutical Co., Ltd
Clinical trials sponsored by Shandong New Time Pharmaceutical Co., Ltd, explained in plain language.
-
New drug combo aims to control Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis study tests a new drug called F182112 given with different treatment plans for people whose multiple myeloma has come back or stopped responding to prior therapies. About 90 participants will receive the drug combination to see if it can shrink tumors and delay cancer growth…
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called F182112 against standard treatments for people with multiple myeloma that has returned or stopped responding to prior therapies. About 261 adults will be randomly assigned to receive either F182112 or usual care. The main goal is to see if F1821…
Phase: PHASE3 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 20, 2026 11:54 UTC